Skip to main content
Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
9.12
+0.14 (1.56%)
At close: Mar 9, 2026, 4:00 PM EDT
10.77
+1.65 (18.09%)
Pre-market: Mar 10, 2026, 4:00 AM EDT

Zevra Therapeutics Revenue

In the year 2025, Zevra Therapeutics had annual revenue of $106.47M with 350.91% growth. Zevra Therapeutics had revenue of $34.13M in the quarter ending December 31, 2025, with 183.36% growth.

Revenue (ttm)
$106.47M
Revenue Growth
+350.91%
P/S Ratio
4.82
Revenue / Employee
$1,804,576
Employees
59
Market Cap
513.43M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025106.47M82.86M350.91%
Dec 31, 202423.61M-3.85M-14.02%
Dec 31, 202327.46M17.30M170.26%
Dec 31, 202210.16M-18.49M-64.53%
Dec 31, 202128.65M15.36M115.61%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
CorMedix 311.71M
Rigel Pharmaceuticals 294.28M
Vanda Pharmaceuticals 216.11M
Century Therapeutics 113.34M
Fulcrum Therapeutics 80.00M
ADC Therapeutics 75.21M
Prothena Corporation 9.68M
Altimmune 41.00K
Revenue Rankings

ZVRA News

More News